Incidence of and risk factors for immune checkpoint inhibitor–related pneumonitis in thoracic malignancies: a prospective multicenter study
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag377 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, 2026. Verfasst von Yoshihiro Kitahara und 28 weiteren Autor:innen. Beteiligte Einrichtung: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Pneumonia, Thoracic Neoplasms. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) have fundamentally changed cancer treatment, but ICI-related pneumonitis (ICI-P) remains a major clinical concern. Although numerous studies have reported its incidence and risk factors, the retrospective nature of these studies makes accurate assessment difficult in a real-world clinical setting. Patients and Methods This prospective multicenter observational study enrolled patients with advanced or recurrent thoracic malignancies treated with nivolumab, pembrolizumab, or atezolizumab. Thoracic high-resolution computed tomography (HRCT) examinations were performed at the start of ICI therapy and at the onset of ICI-P. The primary endpoint was ICI-P incidence. The secondary endpoints included evaluation of risk factors, with a focus on the lung lesions present at ICI initiation. Fine-Gray analyses with 3 models were used to identify risk factors.
Results
Among 614 eligible patients, 78 (12.7%) developed ICI-P. During a median observation period of 14.4 months, 29 patients developed grade ≥3 pneumonitis and 7 patients died owing to ICI-P. In the multivariable Fine-Gray analyses, independent risk factors for ICI-P included heavy smoking history (>50 pack-years; subdistribution hazard ratio [SHR], 1.90; 95% confidence interval [CI], 1.17-3.10), baseline interstitial lung abnormalities (ILAs; SHR, 3.42; 95% CI, 2.05-5.71), use of PD-1 inhibitors (SHR, 2.15; 95% CI, 1.28-3.63), and immunochemotherapy (SHR, 2.16; 95% CI, 1.17-3.98).
Conclusion
In this prospective real-world cohort, the incidence of ICI-P was relatively high, and ILAs detected by HRCT, heavy smoking history, and treatment with a PD-1 inhibitor alone or in combination with cytotoxic chemotherapy were identified as independent risk factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
- Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
- Department of Respiratory Medicine, Seirei Mikatahara General Hospital, Hamamatsu 433-8558, Japan.
- Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka 420-8527, Japan.
- Department of Respiratory Medicine, Iwata City Hospital, Iwata 438-8550, Japan.
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda 426-8677, Japan.
ORCID-Profile: Yoshihiro Kitahara, Naoki Inui, Kazuhiro Asada, Koji Nishimoto, Yusuke Kaida, Yuzo Suzuki, Hironao Hozumi, Noriyuki Enomoto, Tomoyuki Fujisawa, Kumi Ozaki, Shintaro Ichikawa
Zitieren
APA
Kitahara, Y., Inui, N., Koyauchi, T., Asada, K., Nishimoto, K., Matsuura, S., Hashimoto, D., Matsui, T., Fujii, M., Inami, N., Niwa, M., Koda, K., Matsuda, H., Kaida, Y., Ikeda, M., Sato, M., Ito, Y., Inoue, Y., Yasui, H., …, & Suda, T. (2026). Incidence of and risk factors for immune checkpoint inhibitor–related pneumonitis in thoracic malignancies: a prospective multicenter study. The Oncologist. https://doi.org/10.1093/oncolo/oyag377
Vancouver
Kitahara Y, Inui N, Koyauchi T, Asada K, Nishimoto K, Matsuura S, et al. Incidence of and risk factors for immune checkpoint inhibitor–related pneumonitis in thoracic malignancies: a prospective multicenter study. The Oncologist. 2026. doi:10.1093/oncolo/oyag377
BibTeX
@article{Kitahara2026,
author = {Kitahara, Yoshihiro and Inui, Naoki and Koyauchi, Takafumi and Asada, Kazuhiro and Nishimoto, Koji and Matsuura, Shun and Hashimoto, Dai and Matsui, Takashi and Fujii, Masato and Inami, Nao and Niwa, Mitsuru and Koda, Keigo and Matsuda, Hiroyuki and Kaida, Yusuke and Ikeda, Masaki and Sato, Masaki and Ito, Yasuhiro and Inoue, Yusuke and Yasui, Hideki and Karayama, Masato and Suzuki, Yuzo and Hozumi, Hironao and Furuhashi, Kazuki and Enomoto, Noriyuki and Fujisawa, Tomoyuki and Ozaki, Kumi and Ichikawa, Shintaro and Goshima, Satoshi and Suda, Takafumi},
title = {Incidence of and risk factors for immune checkpoint inhibitor–related pneumonitis in thoracic malignancies: a prospective multicenter study},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag377}
}
EUVIMED